Importing Medicines: The Personal Importation Scheme

Three months of paperwork, one border declaration

Forty-two pages. That's roughly how long the TGA's guidance ecosystem for personal importation runs, once you include the relevant sections of the Therapeutic Goods Act 1989, the Poisons Standard, and the biosecurity and customs overlays that sit on top. I've read all of it more than once , occupational hazard , and I still find people genuinely surprised by what it does and doesn't allow.

The Personal Importation Scheme (PIS) is not a loophole. It's a narrow, formally documented pathway that lets Australian residents bring limited quantities of unapproved therapeutic goods into the country for their own personal use. The TGA administers it. The Australian Border Force enforces it. And the rules for medicines that appear in the Poisons Standard , including cannabis-derived products; are a good deal more constrained than the general scheme would suggest.

What the Personal Importation Scheme actually is

The core framework sits under section 18 of the Therapeutic Goods Act 1989 (Cth). In short: a person may import a therapeutic good that would otherwise require ARTG inclusion, provided specific conditions are met. The TGA's published guidance sets those conditions out clearly.

For most non-controlled medicines, the standard allowance is a three-month supply, carried by the individual for personal use, with documentation available on request. "Personal use" is not loosely interpreted, it means the person importing the goods is the intended user, not a family member or friend, and the quantity must be consistent with that use.

You can read more about how the Australian Register of Therapeutic Goods (ARTG) works and why inclusion matters in our glossary. The short version is: a medicine not on the ARTG has not been assessed by the TGA for quality, safety or efficacy for Australian supply, which is part of why the PIS carries conditions rather than being a free-for-all.

Where cannabis products sit in all of this

This is where things get more complex, and where I see the most misunderstanding.

Cannabis-derived medicines in Australia are primarily scheduled under the Poisons Standard as either Schedule 4 (prescription only) or Schedule 8 (controlled drug), depending on their THC content and formulation. Low-dose cannabidiol products meeting specific criteria were down-scheduled to Schedule 3 (pharmacist-only) in 2021 for a narrow range of registered products, but the vast majority of cannabis medicines; particularly anything with meaningful THC, remain Schedule 8 controlled drugs.

Schedule 8 medicines face a tighter version of the PIS. The TGA's guidance specifies that a traveller may bring in a three-month supply of a Schedule 8 medicine under the PIS, but only if they hold a valid Australian prescription for that medicine. Without a prescription, the medicine cannot be imported under the PIS, full stop. There is no self-authorisation pathway for controlled drugs.

And the prescription must come from an Australian-registered medical practitioner. An overseas script, regardless of its legitimacy in the country of origin, does not satisfy the requirement.

The Special Access Scheme and Authorised Prescriber pathways; how they relate

It's worth understanding how the PIS connects (or doesn't connect) to Australia's other access pathways, particularly for people already navigating unapproved medicines.

The Special Access Scheme (SAS) and the Authorised Prescriber pathway are the two primary routes through which Australian patients can access unapproved therapeutic goods, including most medicinal cannabis products, via a prescribing doctor. Both require an Australian prescriber and operate under TGA oversight, they are not the same thing as importing a product yourself.

What this means in practice: if a patient is accessing a medicinal cannabis product through the SAS or an Authorised Prescriber, that product is supplied via Australian-licensed channels, not via personal importation. The PIS is a separate mechanism, primarily relevant to people travelling into Australia who are already legally prescribed a medicine in another jurisdiction and wish to bring a continuing supply.

Honestly, the conflation of these two pathways causes a lot of confusion. I see it in reader questions here regularly.

What documentation travellers need to carry

For a Schedule 8 medicine, including THC-containing cannabis products; the TGA recommends travellers carry:

• A valid Australian prescription for the medicine
• A letter from the prescribing doctor confirming the medicine, dose and duration of supply
• The medicine in its original, labelled packaging
• Quantity consistent with a three-month personal supply

The ABF may inspect the goods at the border. If documentation is inadequate or the quantity exceeds what is consistent with personal use, the goods may be seized. There is no administrative appeal that automatically restores them.

One thing that often catches people out: even if the documentation is in order, individual Australian states and territories have their own Schedule 8 laws, and a legally imported medicine may still face restrictions on how it is possessed, stored or transported within a particular state. The federal PIS does not override state drug law.

Products sourced online from overseas: a different and riskier matter

Ordering cannabis-derived products, or any unapproved therapeutic goods, directly from overseas suppliers and having them mailed to an Australian address is not the Personal Importation Scheme. It is a different situation entirely, and a significantly more problematic one.

The PIS applies to goods carried personally by a traveller. Postal or courier importation of therapeutic goods without TGA import approval is generally prohibited under the Therapeutic Goods Act 1989. The TGA has published guidance making this distinction explicitly. Attempting to import controlled drugs via post, regardless of the source country's legal status for those products, carries serious legal risk under both Commonwealth and state law.

I want to be plain here: this article is not a pathway for sourcing any medicine. The PIS is an administrative accommodation for travellers. It is not a mechanism for circumventing Australia's scheduling and supply framework.

GMP standards and product quality at the border

There's a quality dimension to this that doesn't get enough attention. Medicines approved in other jurisdictions are manufactured to the standards of that jurisdiction. Australia's TGA requires compliance with Good Manufacturing Practice (GMP) for therapeutics goods supplied here; but goods imported under the PIS have not been assessed for GMP compliance. The patient carries whatever quality assurance the overseas regulatory body provided.

For cannabis products specifically, this matters. Cannabinoid content, residual solvent testing, microbial contamination, these vary considerably between jurisdictions and manufacturers. A product that is schedule-compliant to bring in as a personal import is not necessarily tested to the standard an Australian-approved product would be. That's not a reason to panic; it's just a factual limitation of the scheme that users should understand.

I spent a Saturday a few weeks ago, between fixing Trevor (my sourdough starter, currently staging a comeback after a rough fortnight) and a longer road ride out past Stromlo; cross-referencing GMP equivalence tables between EU, Canadian and Australian frameworks. The differences are narrower than they used to be, but they're not zero.

My honest read on the scheme

The PIS is genuinely useful for what it was designed to do: allow people who are already lawfully prescribed medicines to travel without interruption to their supply. For cannabis medicines in particular, where the product may not have an equivalent approved in Australia, it provides a practical accommodation.

But, and I'd argue this strongly, the scheme is administratively under-explained by the TGA for the cannabis context. The published guidance is not wrong, but it assumes a level of familiarity with the Poisons Standard and the distinction between Schedule 4 and Schedule 8 that most patients simply don't have. A traveller who reads "three-month supply" and assumes that covers their prescribed cannabis oil without reading the controlled-drug requirements carefully is going to have a bad time at the border.

Better plain-language guidance, specifically for cannabis medicines and the PIS, would reduce a lot of unnecessary confusion; and a lot of unnecessarily confiscated medicines.

Sources

• Personal Importation Scheme, Therapeutic Goods Administration (TGA)
• Poisons Standard (SUSMP), Federal Register of Legislation
• Good Manufacturing Practice (GMP); Therapeutic Goods Administration (TGA)
• Accessing Unapproved Therapeutic Goods, Therapeutic Goods Administration (TGA)

, Marcus Hale, Regulatory researcher, TGA & access law